suramin has been researched along with Multiple Myeloma in 3 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin has been reported to have major antiproliferative effects in a variety of lymphoid cell lines." | 5.29 | Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. ( Freter, CE; Khera, SY; Miglietta, L; Shiao, RT; Wolfson, A, 1995) |
| "Suramin has been reported to have major antiproliferative effects in a variety of lymphoid cell lines." | 1.29 | Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. ( Freter, CE; Khera, SY; Miglietta, L; Shiao, RT; Wolfson, A, 1995) |
| "Suramin treatment causes a moderate decrease in IgM mRNA, and this is associated with a decreased intracellular level of IgM in SKW 6." | 1.29 | Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines. ( Freter, CE; Khera, SY; McLeskey, SB; Shiao, RT; Wolfson, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiao, RT | 3 |
| Miglietta, L | 1 |
| Khera, SY | 2 |
| Wolfson, A | 2 |
| Freter, CE | 2 |
| McLeskey, SB | 1 |
| Chen, YH | 1 |
| Labayog, JM | 1 |
| Modi, S | 1 |
| Lavelle, D | 1 |
1 review available for suramin and Multiple Myeloma
| Article | Year |
|---|---|
Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma.
Topics: Animals; Antibodies, Monoclonal; Clinical Trials as Topic; Glucocorticoids; Humans; Interferons; Int | 1997 |
2 other studies available for suramin and Multiple Myeloma
| Article | Year |
|---|---|
Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
Topics: Antigens, CD; Apoptosis; B-Lymphocytes; Cell Division; Dexamethasone; DNA; Dose-Response Relationshi | 1995 |
Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Interacti | 1996 |